ArticleFrontiers in oncology2026
Clinically oriented automatic 2D liver tumor segmentation: LCMambaNet with a state-space model and liver cancer-specific attention.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hybrid Neural Network Architecture for Automated Liver and Tumor Segmentation Using Ensemble Learning on CT Images.Biomimetics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liver cancer is among the deadliest malignancies worldwide, and both its incidence and mortality continue to rise. Precise tumor segmentation often remains difficult due to heterogeneous enhancement patterns, infiltrative margins, and frequently obscured underlying parenchymal disease. While deep learning has advanced the field, existing heavy 3D architectures (e.g., nnU-Net) often require substantial computational resources, which limits their clinical deployment. Standard architectures also still struggle to reconcile fine-grained tissue cues with whole-organ context. Methods: This study introduces the Liver Cancer Mamba Network (LCMambaNet), an efficient 2D segmentation framework built on selective state-space models. A tailored scan-patch mechanism extracts salient texture- and density-based features, sharpening the discrimination between normal parenchyma and malignant regions. The Liver Cancer Attention Module (LCAM) further decouples the confounding relationships between parenchymal descriptors and tumor characteristics. The selective state-space backbone captures long-range dependencies and continuous feature dynamics. We evaluated the model on both the LITS (CT) and CirrMR160+ (MRI) datasets. Results: The proposed approach surpasses current state-of-the-art methods, achieving Dice scores of 92.94 ± 3.12% and 92.08 ± 2.85% on the LITS and CirrMR160+ datasets, respectively. Notably, stratified analysis shows superior performance on small lesions (< 2 cm), with statistical significance (p < 0.01) against strong baseline models. Comprehensive ablation studies verify the contribution of each component. Discussion: The results demonstrate that LCMambaNet offers an efficient, clinically viable solution for 2D liver tumor segmentation. Its design addresses the key limitations of existing models, balancing computational efficiency with high segmentation accuracy. The strong performance on small lesions also highlights its potential to support early diagnosis and precise treatment planning, advancing the clinical utility of AI-based segmentation tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.